Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Biologic and therapeutic role of HER2 in cancer

Oncogene volume 22, pages 6570–6578 (2003)Cite this article

Abstract

Overexpression of the human epidermal growth factor-2 (HER2) oncogene in human breast carcinomas has been associated with a more aggressive course of disease. The reason for this association is still unclear, although it has been suggested to rest in increased proliferation, vessel formation, and/or invasiveness. Alternatively, prognosis may not be directly related to the presence of the oncoprotein on the cell membrane, but instead to the breast carcinoma subset identified by HER2 overexpression and characterized by a peculiar gene expression profile. HER2 has also been associated with sensitivity to anthracyclins and resistance to endocrine therapy, suggesting that tyrosine kinase receptor and hormone receptor pathways represent two major proliferation pathways exclusively active in breast carcinomas, one sensitive to chemotherapeutic drugs and the other to antiestrogens. HER2 currently represents one of the most appropriate targets for specific therapy. Indeed, trastuzumab, a monoclonal antibody directed against the extracellular domain of HER2, is therapeutically active in HER2-positive breast carcinomas. However, a consistent number of HER2-positive tumors is not responsive to HER2-driven therapy, indicating the need for a better understanding of the mechanism of action of this new biological drug in vivo. While preclinical studies suggest antibody-dependent cell cytotoxicity as the major mechanism, determination of NK activity at the time of treatment remains mandatory, especially in patients treated with immunosuppressive drugs. The efficacy of prophylactic vaccination has been fully demonstrated in preclinical models, whereas ongoing studies of active immunotherapy using a variety of vaccination regimens against HER2 in tumor-bearing mice and patients have met with only moderate success.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  • Cell Markers and Cytogenetics Committees College of American Pathologist. (2002. Arch. Pathol. Lab. Med. 126, 803–808.

  • Allgayer H, Babic R, Gruetzner KU, Tarabichi A, Schildberg FW and Heiss MM . (2000). J. Clin. Oncol., 18, 2201–2209.

  • Amici A, Smorlesi A, Noce G, Santoni G, Cappelletti P, Capparuccia L, Coppari R, Lucciarini R, Petrelli C and Provinciali M . (2000). Gene Therapy, 7, 703–706.

  • Bocchia M, Bronte V, Colombo MP, De Vincentiis A, Di Nicola M, Forni G, Lanata L, Lemoli RM, Massaia M, Rondelli D, Zanon P and Tura S . (2000). Haematologica, 85, 1172–1206.

  • Bocker W, Moll R, Poremba C, Holland R, Van Diest PJ, Dervan P, Burger H, Wai D, Ina DR, Brandt B, Herbst H, Schmidt A, Lerch MM and Buchwallow IB . (2002). Lab. Invest., 82, 737–746.

  • Burstein HJ, Harris LN, Gelman R, Lester SC, Nunes RA, Kaelin CM, Parker LM, Ellisen LW, Kuter I, Gadd MA, Christian RL, Kennedy PR, Borges VF, Bunnell CA, Younger J, Smith BL and Winer EP . (2003). J. Clin. Oncol., 21, 46–53.

  • Campiglio M, Somenzi G, Olgiati C, Beretta G, Balsari A, Zaffaroni N, Valagussa P and Ménard S . (2003). Int. J. Cancer, 105, 568–573.

  • Campiglio M, Tagliabue E, Uppugunduri S, Pellegrini R, Martignone S, Ménard S, Colnaghi MI, Lombardi L and Marchisio PC . (1994). J. Cell. Biochem., 55, 409–418.

  • Carter P, Presta L, Gorman CM, Ridgway JB, Henner D, Wong WL, Rowland AM, Kotts C, Carver ME and Shepard HM . (1992). Proc. Natl. Acad. Sci. USA, 89, 4285–4289.

  • Casalini P, Botta L and Ménard S . (2001). J. Biol. Chem., 276, 12449–12453.

  • Cavallo F, Di Carlo E, Butera M, Verrua R, Colombo MP, Musiani P and Forni G . (1999). Cancer Res., 59, 414–421.

  • Cavallo F, Signorelli P, Giovarelli M, Musiani P, Modesti A, Brunda MJ, Colombo MP and Forni G . (1997). J. Natl. Cancer Inst., 89, 1049–1058.

  • Cefai D, Morrison BW, Sckell A, Favre L, Balli M, Leunig M and Gimmi CD . (1999). Int. J. Cancer, 83, 393–400.

  • Clynes RA, Towers TL, Presta LG and Ravetch JV . (2000). Nat. Med., 6, 443–446.

  • Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman G and Slamon DJ . (1999). J. Clin. Oncol., 17, 2639–2648.

  • Colombo MP and Forni G . (1996). Cancer Metastasis Rev., 15, 317–328.

  • Cooke T, Reeves J, Lannigan A and Stanton P . (2001). Eur. J. Cancer, 37, 3–10.

  • Coussens L, Yang-Feng TL, Liao Y-C, Chen E, Gray A, McGrath J, Seeburg PH, Libermann FA, Schlessinger J, Francke U, Levinson A and Ullrich A . (1985). Science, 230, 1132–1139.

  • Dakappagari NK, Douglas DB, Triozzi PL, Stevens VC and Kaumaya PT . (2000). Cancer Res., 60, 3782–3789.

  • Daly JM, Jannot CB, Beerli RR, Graus-Porta D, Maurer FG and Hynes NE . (1997). Cancer Res., 57, 3804–3811.

  • Daly JM, Olayioye MA, Wong AM, Neve R, Lane HA, Maurer FG and Hynes NE . (1999). Oncogene, 18, 3440–3451.

  • De Santes K, Slamon D, Anderson SK, Shepard M, Fendly B, Maneval D and Press O . (1992). Cancer Res., 52, 1916–1923.

  • De Vecchi R, Pupa SM, Ménard S and Lollini P-L . (1999). Cancer Res., 59, 4471–4472.

  • Debnath J, Mills KR, Collins NL, Reginato MJ, Muthuswamy SK and Brugge JS . (2002). Cell, 111, 29–40.

  • Di Carlo E, Rovero S, Boggio K, Quaglino E, Amici A, Smorlesi A, Forni G and Musiani P . (2001). Clin. Cancer Res., 7, 830s–837s.

  • Di Fiore PP, Pierce JH, Kraus MH, Segatto O, King CR and Aaronson SA . (1987). Science, 237, 178–182.

  • Di Leo A, Gancberg D, Larsimont D, Tanner M, Jarvinen T, Rouas G, Dolci S, Leroy JY, Paesmans M, Isola J and Piccart MJ . (2002). Clin. Cancer Res., 8, 1107–1116.

  • Disis ML, Calenoff E, McLaughlin G, Murphy AE, Chen W, Groner B, Jeschke M, Lydon N, McGlynn E, Livingston RB, Moe R and Cheever MA . (1994). Cancer Res., 54, 16–20.

  • Disis ML and Cheever MA . (1997a). Adv. Cancer Res., 71, 343–371.

  • Disis ML, Gooley TA, Rinn K, Davis D, Piepkorn M, Cheever MA, Knutson KL and Schiffman K . (2002). J. Clin. Oncol., 20, 2624–2632.

  • Disis ML, Pupa SM, Gralow JR, Dittadi R, Ménard S and Cheever MA . (1997b). J. Clin. Oncol., 15, 3363–3367.

  • Dittmar T, Husemann A, Schewe Y, Nofer JR, Niggemann B, Zanker KS and Brandt BH . (2002). FASEB J., 16, 1823–1825.

  • Early Breast Cancer Trialists' Collaborative Group. (1998). Lancet, 351, 1451–1467.

  • Eccles SA . (2000). Recent Results Cancer Res., 157, 41–54.

  • Elledge RM, Green S, Ciocca D, Pugh R, Allred DC, Clark GM, Hill J, Ravdin P, O'Sullivan J, Martino S and Osborne CK . (1998). Clin. Cancer Res., 4, 7–12.

  • Esserman LJ, Lopez T, Montes R, Bald LN, Fendly BM and Campbell MJ . (1999). Cancer Immunol. Immunother., 47, 337–342.

  • Feldner JC and Brandt BH . (2002). Exp. Cell Res, 272, 93–108.

  • Fendly BM, Winget M, Hudziak RM, Lipari MT, Napier MA and Ullrich A . (1990). Cancer Res., 50, 1550–1558.

  • Finn OJ and Forni G . (2002). Curr. Opin. Immunol., 14, 172–177.

  • Forni G, Lollini PL, Musiani P and Colombo MP . (2000). Cancer Res., 60, 2571–2575.

  • Foy TM, Fanger GR, Hand S, Gerard C, Bruck C and Cheever MA . (2002). Semin. Oncol., 29, 53–61.

  • Franklin WA, Veve R, Hirsch FR, Helfrich BA and Bunn Jr PA . (2002). Semin. Oncol, 29, 3–14.

  • Gambaletta D, Marchetti A, Benedetti L, Mercuric AM, Sacchi A and Falcioni R . (2000). J. Biol. Chem., 275, 10604–10610.

  • Gancberg D, Jarvinen T, Di Leo A, Rouas G, Cardoso F, Paesmans M, Verhest A, Piccart MJ, Isola J and Larsimont D . (2002). Breast Cancer Res Treat., 74, 113–120.

  • Gassmann M, Casagranda F, Orioli D, Simon H, Lai C, Klein R and Lemke G . (1995). Nature, 378, 390–394.

  • Geddert H, Zeriouh M, Wolter M, Heise JW, Gabbert HE and Sarbia M . (2002). Am. J. Clin Pathol., 118, 60–66.

  • Giani C, Casalini P, Pupa SM, De Vecchi R, Ardini E, Colnaghi MI, Giordano A and Ménard S . (1998). Oncogene, 17, 425–432.

  • Goebel SU, Iwamoto M, Raffeld M, Gibril F, Hou W, Serrano J and Jensen RT . (2002). Cancer Res., 62, 3702–3710.

  • Graus-Porta D, Beerli RR, Daly JM and Hynes NE . (1997). EMBO J., 16, 1647–1655.

  • Grunt TW, Saceda M, Martin MB, Lupu R, Dittrich E, Krupitza G, Harant H, Huber H and Dittrich C . (1995). Int. J. Cancer, 63, 560–567.

  • Harari D and Yarden Y . (2000). Oncogene, 19, 6102–6114.

  • Haynes NM, Trapani JA, Teng MW, Jackson JT, Cerruti L, Jane SM, Kershaw MH, Smyth MJ and Darcy PK . (2002). Blood, 100, 3155–3163.

  • Hieken TJ, Mehta RR and Shilkaitis A . (1996). Proc. Annu. Meet. Am. Soc. Clin. Oncol., 15, 113.

  • Hirsch FR, Varella-Garcia M, Franklin WA, Veve R, Chen L, Helfrich B, Zeng C, Baron A and Bunn Jr PA . (2002). Br. J. Cancer, 86, 1449–1456.

  • Huang GC, Hobbs S, Walton M and Epstein RJ . (2002). Br. J. Cancer, 86, 1104–1109.

  • Hudziak RM, Lewis GD, Winget M, Fendly BM, Shepard HM and Ullrich A . (1989). Mol. Cell. Biol., 9, 1165–1172.

  • Izumi Y, Xu L, di Tomaso E, Fukumura D and Jain RK . (2002). Nature, 416, 279–280.

  • Jager E, Jager D and Knuth A . (2002). Curr. Opin. Immunol., 14, 178–182.

  • Karunagaran D, Tzahar E, Beerli RR, Chen XM, Graus-Porta D, Ratzkin BJ, Seger R, Hynes NE and Yarden Y . (1996). EMBO J., 15, 254–264.

  • Kerbel RS, Viloria-Petit A, Klement G and Rak J . (2000). Eur. J. Cancer, 36, 1248–1257.

  • Khan AJ, King BL, Smith BD, Smith GL, DiGiovanna MP, Carter D and Haffty BG . (2002). Clin. Cancer Res., 8, 540–548.

  • Kiessling R, Weil WZ, Herrmann F, Lindencrona JA, Choudhury A, Kono K and Seliger B . (2002). Adv. Cancer Res., 85, 101–144.

  • Kim S, lizuka K, Aguila HL, Weissman IL and Yokoyama WM . (2000). Proc. Natl. Acad. Sci. USA, 97, 2731–2736.

  • Knutson KL, Schiffman K and Disis ML . (2001). J. Clin. Invest., 107, 477–484.

  • Konecny G, Pauletti G, Pegram M, Untch M, Dandekar S, Aguilar Z, Wilson C, Rong HM, Bauerfeind I, Felber M, Wang HJ, Beryt M, Seshadri R, Hepp H and Slamon DJ . (2003). J. Natl. Cancer Inst., 95, 142–153.

  • Kraus MH, Issing W, Miki T, Popescu NC and Aaronson SA . (1989). Proc. Natl. Acad. Sci. USA, 86, 9193–9197.

  • Latif Z, Watters AD, Bartlett JM, Underwood MA and Aitchison M . (2002). BJU Int., 89, 5–9.

  • Lee K-F, Simon H, Chen H, Bates B, Hung M-C and Hauser C . (1995). Nature, 378, 394–398.

  • Liu Y, El-Ashry D, Chen D, Ding IYF and Kern FG . (1995). Breast Cancer Res. Treat., 34, 97–117.

  • Lollini PL and Forni G . (2002). Cancer Immunol. Immunother., 51, 409–416.

  • Ludewig B, Ochsenbein AF, Odermatt B, Paulin D, Hengartner H and Zinkernagel RM . (2000). J. Exp. Med., 191, 795–804.

  • Masood S and Bui MM . (2002). Microsc. Res. Tech., 59, 102–108.

  • Mayordomo JI, Zorina T, Storkus WJ, Zitvogel L, Celluzzi C, Falo LD, Melief CJ, Ildstad ST, Kast WM and DeLeo AB . (1995). Nat. Med., 1, 1297–1302.

  • Ménard S, Balsari A, Casalini P, Tagliabue E, Campiglio M, Bufalino R and Cascinelli N . (2002). Clin. Cancer Res., 8, 520–525.

  • Ménard S, Casalini P, Campiglio M, Pupa SM, Agresti R and Tagliabue E . (2001a). Ann. Oncol., 12, S15–S19.

  • Ménard S, Forti S, Castiglioni F, Agresti R and Balsari A . (2001b). Oncology, 61, 67–72.

  • Ménard S, Pupa SM, Casalini P, Rilke F and Colnaghi MI . (1996). J. Clin. Oncol., 14, 2407.

  • Ménard S, Tagliabue E, Campiglio M and Pupa SM . (2000). J. Cell. Physiol., 182, 150–162.

  • Ménard S, Valagussa P, Pilotti S, Gianni L, Biganzoli E, Boracchi P, Tomasic G, Casalini P, Marubini E, Colnaghi MI, Cascinelli N and Bonadonna G . (2001c). J. Clin. Oncol., 19, 329–335.

  • Meyer D and Birchmeier C . (1995). Nature, 378, 386–390.

  • Miles DW, Harris WH, Gillett CE, Smith P and Barnes DM . (1999). Int. J. Cancer, 84, 354–359.

  • Moliterni A, Ménard S, Valagussa P, Biganzoli E, Boracchi P, Balsari A, Casalini P, Tomasic G, Marubini E, Pilotti S and Bonadonna G . (2003). J. Clin. Oncol., 21, 458–462.

  • Murthy SM, Goldschmidt RA, Rao LN, Ammirati M, Buchmann T and Scanlon EF . (1989). Cancer, 64, 2035–2044.

  • Muthuswamy SK, Li D, Lelievre S, Bissell MJ and Brugge JS . (2001). Nat. Cell. Biol., 3, 785–792.

  • Nagata Y, Furugen R, Hiasa A, Ikeda H, Ohta N, Furukawa K, Nakamura H, Kanematsu T and Shiku H . (1997). J. Immunol., 159, 1336–1343.

  • Nakamura H, Saji H, Ogata A, Hosaka M, Hagiwara M, Kawasaki N and Kato H . (2003). Int. J. Cancer, 103, 61–66.

  • Nanni P, Forni G and Lollini PL . (1999). Ann. Oncol., 10, 261–266.

  • Nanni P, Nicoletti G, De Giovanni C, Landuzzi L, Di Carlo E, Cavallo F, Pupa SM, Rossi I, Colombo MP, Ricci C, Astolfi A, Musiani P, Forni G and Lollini P-L . (2001). J. Exp. Med., 194, 1–12.

  • Nicolini G, Miloso M, Moroni MC, Beguinot L and Scotto L . (1996). J. Biol. Chem., 271, 30290–30296.

  • O-charoenrat P, Rhys-Evans P, Court WJ, Box GM and Eccles SA . (1999). Clin. Exp. Metastasis, 17, 631–639.

  • Ohashi PS and DeFranco AL . (2002). Curr. Opin. Immunol., 14, 744–759.

  • Paik S, Bryant J, Tan-Chiu E, Romond E, Hiller W, Park K, Brown A, Yothers G, Anderson S, Smith R, Wickerham DL and Wolmark N . (2002). J. Natl. Cancer Inst., 94, 852–854.

  • Paik SM, Bryant J, Park CH, Fisher B, Tan-Chiu E, Hyams D, Fisher ER, Lippman ME, Wickerham DL and Wolmark N . (1998). J. Natl. Cancer Inst., 90, 1361–1370.

  • Peles E, Bacus SS, Koski RA, Lu HS, Wen D, Ogden SG, Ben Levy R and Yarden Y . (1992). Cell, 69, 205–216.

  • Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO and Botstein D . (2000). Nature, 406, 747–752.

  • Pierce JH, Arnstein P, DiMarco E, Artrip J, Kraus MH, Lonardo F, Di Fiore PP and Aaronson SA . (1991). Oncogene, 6, 1189–1194.

  • Plowman GD, Green JM, Culouscou J-M, Carlton GW, Rothwell VM and Buckley S . (1993). Nature, 366, 473–475.

  • Prenzel N, Fischer OM, Streit S, Hart S and Ullrich A . (2001). Endocr. Relat. Cancer, 8, 11–31.

  • Press MF, Bernstein L, Thomas PA, Meisner LF, Zhou JY, Ma YL, Hung G, Robinson RA, Harris C, El-Naggar A, Slamon DJ, Phillips RN, Ross JS, Wolman SR and Flom KJ . (1997). J. Clin. Oncol., 15, 2894–2904.

  • Press MF, Cordon-Cardo C and Slamon DJ . (1990). Oncogene, 5, 593–962.

  • Pupa SM, Bufalino R, Invernizzi AM, Andreola S, Rilke F, Lombardi L, Colnaghi MI and Ménard S . (1996). J. Clin. Oncol., 14, 85–94.

  • Pupa SM, Invernizzi AM, Forti S, Nanni P, Lollini PL, Meazza R, Ferrini S and Ménard S . (2001). Gene Therapy, 8, 75–79.

  • Pupa SM, Ménard S, Andreola S and Colnaghi MI . (1993). Cancer Res., 53, 5864–5866.

  • Rhodes A, Jasani B, Anderson E, Dodson AR and Balaton AJ . (2002). Am. J. Clin. Pathol., 118, 408–417.

  • Rilke F, Colnaghi MI, Cascinelli N, Andreola S, Baldini MT, Bufalino R, Della Porta G, Ménard S, Pierotti MA and Testori A . (1991). Int. J. Cancer, 49, 44–49.

  • Roche PC, Suman VJ, Jenkins RB, Davidson NE, Martino S, Kaufman PA, Addo FK, Murphy B, Ingle JN and Perez EA . (2002). J. Natl. Cancer Inst., 94, 855–857.

  • Ross JS, Muraca PJ and Jaffe D . (1998). Mod. Pathol., 11, 26a.

  • Rovero S, Amici A, Carlo ED, Bei R, Nanni P, Quaglino E, Porcedda P, Boggio K, Smorlesi A, Lollini PL, Landuzzi L, Colombo MP, Giovarelli M, Musiani P and Forni G . (2000). J. Immunol., 165, 5133–5142.

  • Sarup JC, Johnson RM, King KL, Fendly BM, Lipari MT, Napier MA, Ullrich A and Shepard HM . (1991). Growth Regul., 1, 72–82.

  • Sfondrini L, Besusso D, Rumio C, Rodolfo M, Menard S and Balsari A . (2002). FASEB J., 16, 1749–1754.

  • Shepard HM, Lewis GD, Sarup JC, Fendly BM, Maneval D, Mordenti J, Figari I, Kotts CE, Palladino MAJ and Ullrich A . (1991). J. Clin. Immunol., 11, 117–127.

  • Sibilia M, Steinbach JP, Stingl L, Aguzzi A and Wagner EF . (1998). EMBO J., 17, 719–731.

  • Sieweke MH and Bissell MJ . (1994). Crit. Rev. Oncog., 5, 297–311.

  • Sirotnak FM, Zakowski MF, Miller VA, Scher HI and Kris MG . (2000). Clin. Cancer Res., 6, 4885–4892.

  • Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SC, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A and Press MF . (1989). Science, 244, 707–712.

  • Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J and Norton L . (2001). N. Engl. J. Med., 344, 783–792.

  • Sliwkowski MX, Lofgren JA, Lewis GD, Hotaling TE, Fendly BM and Fox JA . (1999). Semin. Oncol., 26, 60–70.

  • Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Eystein LP and Borresen-Dale AL . (2001). Proc. Natl. Acad. Sci. USA, 98, 10869–10874.

  • Soule S, Baldridge L, Kirkpatrick K, Cheng L, Gilbert JL, Smith LR, Thurston VC, Vance GH, Einhorn L and Miller K . (2002). J. Clin. Pathol., 55, 656–658.

  • Tagliabue E, Agresti R, Ghirelli C, Morelli D and Ménard S . (2001). Breast Cancer Res. Treat., 70, 155–156.

  • Tagliabue E, Ardini E, Pellegrini R, Campiglio M, Bufalino R, Jeschke M, Groner B, Colnaghi MI and Ménard S . (1996). Br. J. Cancer, 74, 1427–1433.

  • Tagliabue E, Pilotti S, Gianni AM, Ménard S and Colnaghi MI . (1998). Eur. J. Cancer, 34, 1982–1983.

  • Tan M, Yao J and Yu DH . (1997). Cancer Res., 57, 1199–1205.

  • Thor AD, Berry DA, Budman DR, Muss HB, Kute T, Henderson IC, Barcos M, Cirrincione C, Edgerton S, Allred C, Norton L and Liu ET . (1998). J. Natl. Cancer Inst., 90, 1346–1360.

  • Threadgill DW, Dlugosz AA, Hansen LA, Tennenbaum T, Lichti U, Yee D, LaMantia C, Mourton T, Herrup K and Harris RC . (1995). Science, 269, 230–234.

  • Tsavaris N, Kosmas C, Vadiaka M, Kanelopoulos P and Boulamatsis D . (2002). Br. J. Cancer, 87, 21–27.

  • Tzahar E, Waterman H, Chen X, Levkowitz G, Karunagaran D, Lavi S, Ratzkin BJ and Yarden Y . (1996). Mol. Cell. Biol., 16, 5276–5287.

  • Ullrich A, Coussens L, Hayflick JS, Dull TJ, Gray A, Tam AW, Lee J, Yarden Y, Libermann TA, Schlessinger J, Downward J, Mayes ELV, Whittle N, Waterfield MD and Seeburg PH . (1984). Nature, 309, 418–425.

  • Van'T Veer LJ, Dai H, Van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R and Friend SH . (2002). Nature, 415, 530–536.

  • Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ and Press M . (2002). J. Clin. Oncol., 20, 719–726.

  • Volpi A, De Paola F, Nanni O, Granato AM, Bajorko P, Becciolini A, Scarpi E, Riccobon A, Balzi M and Amadori D . (2000). Breast Cancer Res. Treat., 63, 181–192.

  • Waterman H, Alroy I, Strano S, Seger R and Yarden Y . (1999). EMBO J., 18, 3348–3358.

  • Witters L, Engle L and Lipton A . (2002). Oncol Rep., 9, 1163–1166.

  • Yan J, Fang Y, Huang BJ, Liang QW, Wu QL and Zeng YX . (2002). Cancer Genet. Cytogenet., 132, 116–119.

  • Yarden Y . (2001). Eur. J. Cancer, 37, S3–S8.

  • Zhou BP and Hung MC . (2002). Semin. Oncol., 29, 62–70.

  • Zitvogel L, Mayordomo JI, Tjandrawan T, DeLeo AB, Clarke MR, Lotze MT and Storkus WJ . (1996). J. Exp. Med., 183, 87–97.

Download references

Acknowledgements

This work was partially supported by Associazione Italiana per la Ricerca sul Cancro and by Cariplo.

Author information

Authors and Affiliations

  1. Department of Experimental Oncology, Molecular Targeting Unit, Istituto Nazionale Tumori, Milan, 20133, Italy

    Sylvie Ménard, Serenella Marja Pupa, Manuela Campiglio & Elda Tagliabue

Authors
  1. Sylvie Ménard
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Serenella Marja Pupa
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Manuela Campiglio
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Elda Tagliabue
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sylvie Ménard.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ménard, S., Pupa, S., Campiglio, M. et al. Biologic and therapeutic role of HER2 in cancer. Oncogene 22, 6570–6578 (2003). https://doi.org/10.1038/sj.onc.1206779

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1206779

Keywords

This article is cited by

Search

Advanced search

Quick links